1
|
Pavek P, Dusek J, Smutny T, Lochman L, Kucera R, Skoda J, Smutna L, Kamaraj R, Soucek P, Vrzal R, Dvorak Z. Gene expression profiling of 1α,25(OH)
2
D
3
treatment in 2D/3D human hepatocyte models reveals CYP3A4 induction but minor changes in other xenobiotic‐metabolizing genes. Mol Nutr Food Res 2022; 66:e2200070. [DOI: 10.1002/mnfr.202200070] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2022] [Indexed: 11/08/2022]
Affiliation(s)
- Petr Pavek
- Department of Pharmacology and Toxicology Faculty of Pharmacy in Hradec Kralove Charles University Hradec Kralove Czech Republic
| | - Jan Dusek
- Department of Pharmacology and Toxicology Faculty of Pharmacy in Hradec Kralove Charles University Hradec Kralove Czech Republic
| | - Tomas Smutny
- Department of Pharmacology and Toxicology Faculty of Pharmacy in Hradec Kralove Charles University Hradec Kralove Czech Republic
| | - Lukas Lochman
- Department of Pharmaceutical Chemistry and Pharmaceutical Analysis Faculty of Pharmacy in Hradec Kralove Charles University Hradec Kralove Czech Republic
| | - Radim Kucera
- Department of Pharmaceutical Chemistry and Pharmaceutical Analysis Faculty of Pharmacy in Hradec Kralove Charles University Hradec Kralove Czech Republic
| | - Josef Skoda
- Department of Pharmacology and Toxicology Faculty of Pharmacy in Hradec Kralove Charles University Hradec Kralove Czech Republic
| | - Lucie Smutna
- Department of Pharmacology and Toxicology Faculty of Pharmacy in Hradec Kralove Charles University Hradec Kralove Czech Republic
| | - Rajamanikkam Kamaraj
- Department of Pharmacology and Toxicology Faculty of Pharmacy in Hradec Kralove Charles University Hradec Kralove Czech Republic
| | - Pavel Soucek
- Toxicogenomics Unit National Institute of Public Health Prague Czech Republic
- Laboratory of Pharmacogenomics Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic
| | - Radim Vrzal
- Department of Cell Biology and Genetics Faculty of Science Palacky University Olomouc Czech Republic
| | - Zdenek Dvorak
- Department of Cell Biology and Genetics Faculty of Science Palacky University Olomouc Czech Republic
| |
Collapse
|
2
|
Suzuki K, Taniyama K, Aoyama T, Watanabe Y. Evaluation of the Role of P-glycoprotein (P-gp)-Mediated Efflux in the Intestinal Absorption of Common Substrates with Elacridar, a P-gp Inhibitor, in Rats. Eur J Drug Metab Pharmacokinet 2020; 45:385-392. [PMID: 32078103 DOI: 10.1007/s13318-019-00602-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND AND OBJECTIVES P-glycoprotein (P-gp) has been shown previously to contribute to the intestinal absorption of verapamil, diltiazem, tacrolimus, colchicine and indinavir in situ; however, its contribution in vivo is unknown. The present study aimed to evaluate the in vivo involvement of P-gp using elacridar as its inhibitor to distinguish the contribution of P-gp from cytochrome P450 (CYP) 3A. METHODS Fexofenadine (5 mg/kg) and buspirone (1 mg/kg) were used as probe substrates of P-gp and CYP3A, respectively. Each dual substrate (1 or 2 mg/kg) was orally administered to rats after elacridar pre-treatment (3 mg/kg). Additionally, verapamil, diltiazem or tacrolimus was orally co-administered with fexofenadine. RESULTS Elacridar drastically increased the area under the plasma concentration-time curve (AUC0-t) of oral fexofenadine by 8.6-fold; however, it did not affect the AUC0-t of oral buspirone. Therefore, elacridar inhibited P-gp without affecting CYP3A. The absorption of oral verapamil, diltiazem and tacrolimus was not influenced by elacridar pre-treatment, and the increase in the AUC0-t of fexofenadine was approximately 3-fold when co-administered with each substrate; the minimal effect of elacridar was attributable to the limited contribution of P-gp but not to their self-inhibition against the transporter. Conversely, elacridar significantly increased the AUC0-t of colchicine (5.3-fold) and indinavir (2.0-fold), indicating that P-gp contributes to their absorption. CONCLUSIONS Elacridar is useful for distinguishing the contribution of P-gp from CYP3A to the absorption of drugs in rats. The in vivo contribution of P-gp is minimal for high permeable compounds owing to their fraction absorbed of nearly 1.0.
Collapse
Affiliation(s)
- Kei Suzuki
- Exploratory Research Section III, Exploratory Research Laboratories, Drug Research Department, TOA EIYO LTD., 1, Yuno-tanaka, Iizaka-machi, Fukushima-shi, Fukushima, 960-0280, Japan.
| | - Kazuhiro Taniyama
- Exploratory Research Section III, Exploratory Research Laboratories, Drug Research Department, TOA EIYO LTD., 1, Yuno-tanaka, Iizaka-machi, Fukushima-shi, Fukushima, 960-0280, Japan.
| | - Takao Aoyama
- Faculty of Pharmaceutical Science, Tokyo University of Science, Noda, Chiba, Japan
| | - Yoshiaki Watanabe
- Exploratory Research Section III, Exploratory Research Laboratories, Drug Research Department, TOA EIYO LTD., 1, Yuno-tanaka, Iizaka-machi, Fukushima-shi, Fukushima, 960-0280, Japan
| |
Collapse
|
3
|
Suzuki K, Taniyama K, Aoyama T, Watanabe Y. Usefulness of novobiocin as a selective inhibitor of intestinal breast cancer resistance protein (Bcrp) in rats. Xenobiotica 2020; 50:1121-1127. [DOI: 10.1080/00498254.2019.1708514] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Affiliation(s)
- Kei Suzuki
- Exploratory Research Laboratories, Drug Research department, TOA EIYO LTD., Fukushima, Japan
| | - Kazuhiro Taniyama
- Exploratory Research Laboratories, Drug Research department, TOA EIYO LTD., Fukushima, Japan
| | - Takao Aoyama
- Faculty of Pharmaceutical Science, Tokyo University of Science, Chiba, Japan
| | - Yoshiaki Watanabe
- Exploratory Research Laboratories, Drug Research department, TOA EIYO LTD., Fukushima, Japan
| |
Collapse
|
4
|
Xing H, Ren C, Kong Y, Ning C, Kong D, Zhang Y, Zhao D, Li N, Wang Z, Chen X, Lu Y. Mechanistic study of absorption and first-pass metabolism of GL-V9, a derivative of wogonin. Biopharm Drug Dispos 2019; 40:151-161. [PMID: 30931529 DOI: 10.1002/bdd.2179] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2018] [Revised: 02/07/2019] [Accepted: 03/14/2019] [Indexed: 01/17/2023]
Abstract
GL-V9, a derivative of wogonin, has potent anti-cancer activity. The absorption and metabolism of this compound have not been investigated systematically. This study aims to illustrate the pharmacokinetic characters of GL-V9 by exploring its metabolic status under different administration routes. To further clarify the absorption mechanism of GL-V9, an in situ single-pass perfusion model and a Caco-2 cell monolayer model were used. Meanwhile, a microsomal incubation system was used to evaluate the enzyme kinetic parameters. In vivo, the obtained gastrointestinal availability (Fa × Fg ) was 21.28 ± 5.38%. The unmetabolized fraction in the gut wall (Fgut wall ) was 98.59 ± 9.74%, while the hepatic bioavailability (Fh ) was 29.11 ± 5.22%. These results indicated that poor absorption and extensive metabolism may contribute greatly to the low bioavailability of GL-V9. The effective permeability (Peff ) in the duodenum and jejunum was 1.34 ± 0.50 × 10-4 and 0.90 ± 0.27 × 10-4 cm/s, respectively. The high permeability of GL-V9 indicated that other unknown factors (such as metabolism) may account for its systemic exposure problem. Studies in rat liver microsomal (RLMs) confirmed this hypothesis, and the Clint, CYP450s and UGT of GL-V9 was 0.20 ml/min/mg protein. In conclusion, these results suggest that GL-V9 possesses higher permeability than wogonin and the metabolism of GL-V9 is related to its disposition in rat intestine and liver.
Collapse
Affiliation(s)
- Han Xing
- Clinical Pharmacokinetics Laboratory, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, China
| | - Chang Ren
- Clinical Pharmacokinetics Laboratory, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, China
| | - Ying Kong
- Clinical Pharmacokinetics Laboratory, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, China
| | - Chen Ning
- Clinical Pharmacokinetics Laboratory, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, China
| | - Dexuan Kong
- Clinical Pharmacokinetics Laboratory, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, China
| | - Yongjie Zhang
- Clinical Pharmacokinetics Laboratory, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, China
| | - Di Zhao
- Clinical Pharmacokinetics Laboratory, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, China
| | - Ning Li
- Clinical Pharmacokinetics Laboratory, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, China
| | - Zeyu Wang
- Clinical Pharmacokinetics Laboratory, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, China
| | - Xijing Chen
- Clinical Pharmacokinetics Laboratory, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, China
| | - Yang Lu
- Clinical Pharmacokinetics Laboratory, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, China
| |
Collapse
|
5
|
Hyrsova L, Vanduchova A, Dusek J, Smutny T, Carazo A, Maresova V, Trejtnar F, Barta P, Anzenbacher P, Dvorak Z, Pavek P. Trans-resveratrol, but not other natural stilbenes occurring in food, carries the risk of drug-food interaction via inhibition of cytochrome P450 enzymes or interaction with xenosensor receptors. Toxicol Lett 2018; 300:81-91. [PMID: 30394306 DOI: 10.1016/j.toxlet.2018.10.028] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2018] [Revised: 09/03/2018] [Accepted: 10/08/2018] [Indexed: 01/27/2023]
Abstract
Resveratrol (RSV) is a stilbene phytochemical common in food and red wine. RSV inhibits cytochrome P450 CYP3A4 activity and interacts with the pregnane X receptor (PXR), the central regulator of drug/xenobiotic metabolizing enzyme expression. In this work, we comprehensively examined the effects of 13 stilbenes (trans- and cis-resveratrol, trans- and cis-piceatannol, oxyresveratrol, pterostilbene, pinostilbene, a,b-dihydroresveratrol, trans- and cis-trismethoxyresveratrol, trans-3,4,5,4'-tetramethoxystilbene, trans-2,4,3',5'-tetramethoxystilbene, trans-4-methoxystilbene), on CYP3A4 and CYP2B6 mRNA induction, and on CYP3A4/5, CYP2C8/9/19, CYP2D6, CYP2A6, CYP2E1, CYP1A2 and CYP2B6 cytochrome P450 enzyme activities. Expression experiments in five different primary human hepatocyte preparations, reporter gene assays, and ligand binding assays with pregnane X (PXR) and constitutive androstane (CAR) receptors were performed. Inhibition of cytochrome P450 enzymes was examined in human microsomes. We found that only polymethoxylated stilbenes are prone to significantly induce CYP2B6 or CYP3A4 in primary human hepatocytes via pregnane X receptor (PXR) interaction. Natural resveratrol derivatives such as trans- and cis-RSV, oxyresveratrol, pinostilbene and pterostilbene significantly inhibit CYP3A4/5 enzymatic activities; however, only trans-RSV significantly inhibits CYP3A4/5 activity (both testosterone 6β-hydroxylation and midazolam 1´-hydroxylation) in micromolar concentrations by a non-competitive mechanism, suggesting a potential risk of food-drug interactions with CYP3A4/5 substrates.
Collapse
Affiliation(s)
- Lucie Hyrsova
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, Hradec Kralove, CZ500 05, Czech Republic
| | - Alena Vanduchova
- Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 3, CZ775 15, Olomouc, Czech Republic; Institute of Molecular and Translational Medicine (IMTM), Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 3, CZ775 15, Olomouc, Czech Republic
| | - Jan Dusek
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, Hradec Kralove, CZ500 05, Czech Republic
| | - Tomas Smutny
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, Hradec Kralove, CZ500 05, Czech Republic
| | - Alejandro Carazo
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, Hradec Kralove, CZ500 05, Czech Republic; Institute of Molecular and Translational Medicine (IMTM), Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 3, CZ775 15, Olomouc, Czech Republic
| | - Veronika Maresova
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, Hradec Kralove, CZ500 05, Czech Republic
| | - Frantisek Trejtnar
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, Hradec Kralove, CZ500 05, Czech Republic
| | - Pavel Barta
- Department of Biophysics and Physical Chemistry, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, Hradec Kralove, CZ500 05, Czech Republic
| | - Pavel Anzenbacher
- Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 3, CZ775 15, Olomouc, Czech Republic
| | - Zdenek Dvorak
- Department of Cellular Biology and Genetics, Faculty of Sciences, Palacky University in Olomouc, Slechtitelu 27, 783 71, Olomouc, Czech Republic
| | - Petr Pavek
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, Hradec Kralove, CZ500 05, Czech Republic.
| |
Collapse
|
6
|
Yamamoto S, Kosugi Y, Hirabayashi H, Moriwaki T. Impact of P-Glycoprotein on Intestinal Absorption of an Inhibitor of Apoptosis Protein Antagonist in Rats: Mechanisms of Nonlinear Pharmacokinetics and Food Effects. Pharm Res 2018; 35:190. [PMID: 30105478 DOI: 10.1007/s11095-018-2470-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2018] [Accepted: 07/31/2018] [Indexed: 10/28/2022]
Abstract
PURPOSE This study was designed to investigate the effects of P-glycoprotein (P-gp) expressed in the intestine on the nonlinear pharmacokinetics (PK) of T-3256336, an inhibitor of apoptosis protein inhibitor, and food effects on its bioavailability in rats. METHODS To investigate the factors that contribute to nonlinear PK of T-3256336 in the intestine and liver, rats double-cannulated in the portal vein and femoral artery (PS rats) were used. FaFg (Fa, absorption ratio; Fg, intestinal availability) and hepatic availability (Fh) were simultaneously evaluated based on the difference between the portal and systemic blood area under the concentration-time curve (AUC). Elacridar was used as a P-gp inhibitor to assess the impact of P-gp on the intestinal absorption. RESULTS After oral administration of T-3256336 to PS rats at 3 and 30 mg/kg, FaFg value increased with dose escalation, whereas Fh value was nearly constant. Moreover, co-administration of elacridar resulted in a 5-fold increase in the FaFg value at 3 mg/kg. The AUC value of T-3256336 under fed conditions was 3-fold lower than that under fasted conditions. This food effect on the oral bioavailability (BA) was reduced by concomitant administration of elacridar. CONCLUSION P-gp expressed in the intestine would cause nonlinear PK and a food effect on BA of T-3256336 in rats.
Collapse
Affiliation(s)
- Syunsuke Yamamoto
- Drug Metabolism and Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, Japan.
| | - Yohei Kosugi
- Drug Metabolism and Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, Japan
| | - Hideki Hirabayashi
- Drug Metabolism and Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, Japan
| | - Toshiya Moriwaki
- Drug Metabolism and Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, Japan
| |
Collapse
|
7
|
Raje AA, Deshpande RD, Pathade VV, Mahajan V, Joshi K, Tambe A, Jinugu R, Madgula VLM, Gaur A, Kandikere V, Patil CR, Mookhtiar KA. Evaluation of separate role of intestine and liver in first pass metabolism of budesonide in rat. Xenobiotica 2017; 48:1206-1214. [PMID: 29165024 DOI: 10.1080/00498254.2017.1404168] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
1. Budesonide, a potent topical corticosteroid, reported to have low oral bioavailability in mice, rat, dog and human due to rapid first pass metabolism. However, there is insufficient information available in literature regarding the role of intestine and or liver responsible for the first pass metabolism of budesonide. 2. Current study in rats investigates the role of intestine and liver in first pass metabolism of budesonide using two in vivo models. Additionally, budesonide was also evaluated in in vitro assays such as thermodynamic solubility, permeability in Caco-2 cells and stability in simulated gastric (SGF), intestinal fluids (SIF) to understand the underlaying cause for low oral bioavailability. 3. Budesonide showed low oral, intra-duodenal and high intra-portal bioavailability in rat. In a dual vein cannulated rat model, intestinal and hepatic extraction ratios calculated based upon intestinal availability (Fa·Fg) and hepatic availability (Fh), suggests hepatic extraction of budesonide is minimal compared to intestinal. 4. In vitro results suggest, solubility and permeability may not be a barrier for the observed low oral bioavailability in rats. 5. Correlating the in vitro and in vivo data together, it can be concluded that, intestine might be playing major role in first pass metabolism of budesonide.
Collapse
Affiliation(s)
- Amol A Raje
- a Clinical Candidate Optimization, Drug Discovery Unit, Advinus Therapeutics Ltd , Pune , India and
| | - Radni D Deshpande
- b Department of Pharmacology , R. C. Patel Institute of Pharmaceutical Education and Research , Shirpur , India
| | - Vishal V Pathade
- a Clinical Candidate Optimization, Drug Discovery Unit, Advinus Therapeutics Ltd , Pune , India and
| | - Vallabh Mahajan
- a Clinical Candidate Optimization, Drug Discovery Unit, Advinus Therapeutics Ltd , Pune , India and
| | - Kaushal Joshi
- a Clinical Candidate Optimization, Drug Discovery Unit, Advinus Therapeutics Ltd , Pune , India and
| | - Ashwini Tambe
- a Clinical Candidate Optimization, Drug Discovery Unit, Advinus Therapeutics Ltd , Pune , India and
| | - Ramana Jinugu
- a Clinical Candidate Optimization, Drug Discovery Unit, Advinus Therapeutics Ltd , Pune , India and
| | - Vamsi L M Madgula
- a Clinical Candidate Optimization, Drug Discovery Unit, Advinus Therapeutics Ltd , Pune , India and
| | - Ashwani Gaur
- a Clinical Candidate Optimization, Drug Discovery Unit, Advinus Therapeutics Ltd , Pune , India and
| | - Vishwottam Kandikere
- a Clinical Candidate Optimization, Drug Discovery Unit, Advinus Therapeutics Ltd , Pune , India and
| | - Chandragouda R Patil
- b Department of Pharmacology , R. C. Patel Institute of Pharmaceutical Education and Research , Shirpur , India
| | - Kasim A Mookhtiar
- a Clinical Candidate Optimization, Drug Discovery Unit, Advinus Therapeutics Ltd , Pune , India and
| |
Collapse
|
8
|
Dusek J, Carazo A, Trejtnar F, Hyrsova L, Holas O, Smutny T, Micuda S, Pavek P. Steviol, an aglycone of steviol glycoside sweeteners, interacts with the pregnane X (PXR) and aryl hydrocarbon (AHR) receptors in detoxification regulation. Food Chem Toxicol 2017; 109:130-142. [DOI: 10.1016/j.fct.2017.09.007] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2017] [Revised: 08/20/2017] [Accepted: 09/01/2017] [Indexed: 01/01/2023]
|
9
|
Uchida M, Tajima Y, Kakuni M, Kageyama Y, Okada T, Sakurada E, Tateno C, Hayashi R. Organic Anion–Transporting Polypeptide (OATP)–Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver. Drug Metab Dispos 2017; 46:11-19. [DOI: 10.1124/dmd.117.075994] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2017] [Accepted: 10/13/2017] [Indexed: 01/13/2023] Open
|
10
|
Peters SA, Jones CR, Ungell AL, Hatley OJD. Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models. Clin Pharmacokinet 2016; 55:673-96. [PMID: 26895020 PMCID: PMC4875961 DOI: 10.1007/s40262-015-0351-6] [Citation(s) in RCA: 58] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Intestinal metabolism can limit oral bioavailability of drugs and increase the risk of drug interactions. It is therefore important to be able to predict and quantify it in drug discovery and early development. In recent years, a plethora of models-in vivo, in situ and in vitro-have been discussed in the literature. The primary objective of this review is to summarize the current knowledge in the quantitative prediction of gut-wall metabolism. As well as discussing the successes of current models for intestinal metabolism, the challenges in the establishment of good preclinical models are highlighted, including species differences in the isoforms; regional abundances and activities of drug metabolizing enzymes; the interplay of enzyme-transporter proteins; and lack of knowledge on enzyme abundances and availability of empirical scaling factors. Due to its broad specificity and high abundance in the intestine, CYP3A is the enzyme that is frequently implicated in human gut metabolism and is therefore the major focus of this review. A strategy to assess the impact of gut wall metabolism on oral bioavailability during drug discovery and early development phases is presented. Current gaps in the mechanistic understanding and the prediction of gut metabolism are highlighted, with suggestions on how they can be overcome in the future.
Collapse
Affiliation(s)
- Sheila Annie Peters
- Translational Quantitative Pharmacology, BioPharma, R&D Global Early Development, Merck KGaA, Frankfurter Str. 250, F130/005, 64293, Darmstadt, Germany.
| | | | - Anna-Lena Ungell
- Investigative ADME, Non-Clinical Development, UCB New Medicines, BioPharma SPRL, Braine l'Alleud, Belgium
| | - Oliver J D Hatley
- Simcyp Limited (A Certara Company), Blades Enterprise Centre, Sheffield, UK
| |
Collapse
|
11
|
Xiao Q, Yang W, Wang D, Chen L, Yuan L, Ding Y, Yang J. Factors limiting the extent of absolute bioavailability of pradefovir in rat. Xenobiotica 2016; 46:913-21. [DOI: 10.3109/00498254.2015.1133866] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- Qingqing Xiao
- Department of Clinical Pharmacy, China Pharmaceutical University, Nanjing, China,
| | - Wanqiu Yang
- Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China, and
| | - Dan Wang
- Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China, and
| | - Lin Chen
- Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China, and
| | - Linwen Yuan
- Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China, and
| | - Yitao Ding
- Department of Hepatobiliary Surgery, Affiliated Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing, China
| | - Jin Yang
- Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China, and
| |
Collapse
|
12
|
Pu QH, Shi L, Yu C. Time-dependent inhibition of CYP3A4 by gallic acid in human liver microsomes and recombinant systems. Xenobiotica 2014; 45:213-7. [PMID: 25322914 DOI: 10.3109/00498254.2014.973470] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
1.Gallic acid is a main polyphenol in various fruits and plants. Inhibitory characteristics of gallic acid on CYP3A4 were still unclear. The objective of this work is hence to investigate inhibitory characteristics of gallic acid on CYP3A4 using testosterone as the probe substrate in human liver microsomes (HLMs) and recombinant CYP3A4 (rCYP3A4) systems. 2.Gallic acid caused concentration-dependent loss of CYP3A4 activity with IC50 values of 615.2 μM and 669.5 μM in HLM and rCYP3A4 systems, respectively. IC50-shift experiments showed that pre-incubation with gallic acid in the absence of NADPH contributed to 12- or 14-fold reduction of IC50 in HLM and rCYP3A4 systems, respectively, supporting a time-dependent inhibition. In HLM, time-dependent inactivation variables KI and Kinact were 485.8 μM and 0.05 min(-1), respectively. 3.Compared with the presence of NADPH, pre-incubation of gallic acid in the absence of NADPH markedly increased its inhibitory effects in HLM and rCYP3A4 systems. Those results indicate that CYP3A4 inactivation by gallic acid was independent on NADPH and was mainly mediated its oxidative products. 4.In conclusion, we showed that gallic acid weakly and time-dependently inactivated CYP3A4 via its oxidative products.
Collapse
Affiliation(s)
- Qiang-Hong Pu
- Institute of Life Science, Chongqing Medical University , Chongqing , P. R. China
| | | | | |
Collapse
|